ERCC5 Gene Xeroderma Pigmentosum Group G NGS Genetic Test in UAE

Executive Summary & Core Metrics

This advanced genetic screening test provides comprehensive analysis of the ERCC5 gene associated with Xeroderma Pigmentosum Group G using Next Generation Sequencing (NGS). The test delivers 99.9% diagnostic sensitivity per ISO 9001:2015 accreditation and full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. We offer VIP mobile phlebotomy and temperature-controlled cold-chain home collection across Dubai Healthcare City.

✓Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO accredited NGS processing.

✓Premium Logistics: Hospital-grade home collection via ISO certified cold-chain and VIP mobile phlebotomy.

✓Clinical Guidance: Telephonic post-test clinical result interpretation included.

✓Insurance: Direct billing verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This next-generation sequencing test analyzes the entire coding region of the ERCC5 gene to diagnose Xeroderma Pigmentosum Group G, a rare autosomal recessive disorder causing extreme UV sensitivity and elevated skin cancer risk. It is a cornerstone for dermatologists, oncologists, and clinical geneticists in the UAE to guide early intervention, genetic counselling, and personalized prevention plans.

Feature	Our Test	Closest Alternative
Precision	99.9% diagnostic sensitivity (NGS full-gene coverage)	Variable; often Sanger sequencing or targeted panels with limited mutation detection
Methodology	Next Generation Sequencing (NGS) with bioinformatic depth ≥100x	Sanger sequencing or hotspot-only gene panels
Turnaround Time	3 to 4 weeks with integrated genetic counselling support	4 to 6 weeks, often without pre/post-test counselling

Physician Insight & Safety Protocols

“As a consultant medical genetics specialist, I consider this test essential for patients with clinical suspicion of Xeroderma Pigmentosum. Early molecular confirmation enables tailored sun-protection strategies, cancer surveillance, and informed family planning. Genetic counselling should always accompany these results.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory Precautions

Medication Safety Alert

Do not discontinue any prescribed medication without consulting your doctor. This genetic test does not replace ongoing clinical management.

Exclusion Criteria

Safety Net & Exclusion Criteria

Exclusion Criteria: This test is not designed for asymptomatic individuals without clinical suspicion or relevant family history; it is not a general population screening tool.
Red Flags – Seek Immediate Specialist Care: New or changing skin lesions, progressive ataxia, sensorineural hearing loss, or severe photosensitivity with blistering require urgent dermatological/neurological evaluation.
Emergency Warning: In case of acute sunburn-like reaction or unexplained neurological symptoms, proceed to the nearest emergency department.

Patient FAQ & Clinical Guidance

1. What is the ERCC5 gene test and why is it ordered?

The ERCC5 gene test identifies pathogenic variants linked to Xeroderma Pigmentosum Group G for accurate clinical diagnosis and genetic counselling. It is ordered when a patient presents with extreme UV sensitivity, early onset skin cancers, or neurological symptoms suggestive of this rare disorder.

2. How is the sample collected and what is the turnaround time?

A peripheral whole blood sample is collected via our VIP mobile phlebotomy service within a temperature-controlled cold chain. Results are delivered within 3 to 4 weeks, inclusive of a telephonic clinical interpretation session.

3. Is this test covered by insurance in the UAE?

Many UAE insurance plans cover genetic testing when deemed medically necessary. Contact our support team via WhatsApp at +971 54 548 8731 to verify direct billing eligibility for your specific policy.

UAE Regulatory & Data Privacy Adherence

Accreditation & Regulatory Compliance

ISO 9001:2015 Certified – Cert: INT/EGQ/2509DA/3139
DHA Facility License: 1143
Compliance: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Methodology: NGS (Next Generation Sequencing) with full gene coverage.

Clinical & Logistical Metadata

Test Name	ERCC5 Gene Xeroderma Pigmentosum Group G NGS Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3 to 4 weeks
Sample Type / Matrix	Peripheral whole blood (EDTA) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Methodology Used	Next Generation Sequencing (NGS) with bioinformatic depth ≥100x
ICD-10-CM Code	Q82.1, Z15.01, Z84.0
LOINC Code	101418-7
DHA Facility License & Address	License No: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| Corporate Lab Branding: DNA Labs UAE